In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme.
Denis AngoulvantS Granjeon-NoriotP AmarencoA BastienE BechetF BoccaraJ P BoisselB CariouE CourcellesA DiatchenkoA FilipovicsR KahoulG MahéE PeyronnetL PortalS PorteY WangP G StegPublished in: European journal of preventive cardiology (2024)
The SIRIUS in-silico trial programme will provide early insights regarding a potential effect of inclisiran on MACE in ASCVD patients, several years before the availability of the results from ongoing CV outcomes trials (ORION-4 and VICTORION-2-P).
Keyphrases
- study protocol
- end stage renal disease
- clinical trial
- phase iii
- molecular docking
- ejection fraction
- chronic kidney disease
- newly diagnosed
- randomized controlled trial
- phase ii
- peritoneal dialysis
- type diabetes
- prognostic factors
- skeletal muscle
- open label
- risk assessment
- adipose tissue
- insulin resistance
- placebo controlled